Quick Answer
| A compounded peptide would be | It is not |
|---|---|
| Prepared by a licensed pharmacy for one patient's valid prescription | A bulk-manufactured, mass-produced drug |
| Overseen by the FDA and a state pharmacy board | A "research use only" vial bought online |
| Legal only for a substance that meets specific 503A conditions | Currently possible for most research peptides, including BPC-157 |
What Is Pharmacy Compounding?
Pharmacy compounding is the practice of a licensed pharmacist, or a physician, customizing a medication for an individual patient's specific needs. It's a long-standing part of pharmacy practice, not a workaround or a loophole. Common, everyday reasons a prescriber might ask for a compounded medication include removing an ingredient a patient is allergic to, adjusting a dose or strength that isn't commercially available, changing the delivery form, for example turning a pill into a liquid or a cream for a patient who can't swallow tablets, or preparing a drug that's in shortage or has been discontinued by its original manufacturer.
The key distinction is that compounding is patient-specific. A compounding pharmacy isn't mass-producing a standardized product for the general market the way a pharmaceutical manufacturer does. It's preparing a customized version of a medication for one patient, based on a prescriber's order, which is also why compounded drugs are regulated differently than manufactured ones.
Two Regulatory Pathways: 503A vs 503B
Compounding in the United States generally happens under one of two sections of the Federal Food, Drug, and Cosmetic Act.
- Section 503A covers traditional pharmacy compounding. It's tied to an individual patient's valid prescription and is carried out by a licensed pharmacy or physician. This is the pathway most relevant to peptides, and it's the focus of this article.
- Section 503B covers outsourcing facilities. These can compound in larger batches without a patient-specific prescription on file for each preparation, but they operate under a different, and generally stricter, set of FDA requirements than 503A pharmacies.
Both pathways exist to serve real clinical needs, but they're governed by different rules. Since the current conversation around research peptides centers on individual-patient prescribing, the rest of this article focuses on 503A.
The Three Conditions for Legal Compounding Under 503A
For a compounding pharmacy to legally prepare a substance under Section 503A, that substance generally has to meet one of three conditions:
- It appears on the FDA's 503A Bulk Drug Substances List, sometimes called the 503A Bulks List.
- It has its own official USP or NF monograph, meaning it's already recognized in the U.S. Pharmacopoeia or National Formulary with established quality standards.
- It's a component of an already FDA-approved drug.
This is exactly why the 503A Bulks List matters so much for peptides. Most of the research peptides discussed online, including BPC-157, TB-500, and MOTS-c, don't have a USP or NF monograph and aren't a component of an FDA-approved drug. That leaves the Bulks List as the realistic path for any of them to become legally compoundable. For a deeper look at how that list works and how substances get added to it, see What Is FDA's 503A Bulks List?
Where Research Peptides Stand Today
As of this writing, none of the commonly discussed research peptides, including BPC-157, TB-500, MOTS-c, KPV, Semax, Epithalon, CJC-1295, Ipamorelin, Selank, or DSIP, are on the 503A Bulks List. That means a compounding pharmacy cannot legally prepare any of them under Section 503A today.
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of these peptides, BPC-157, KPV, TB-500, MOTS-c, Semax, and Epithalon, for future inclusion on the 503A Bulks List. That's a meaningful development, but it's important to be precise about what it is: a nonbinding recommendation, not a final rule. The FDA still has to decide whether, and how, to act on it. For the full breakdown of that vote and what would still need to happen for it to translate into an actual rule change, see What Changed With BPC-157, TB-500 and MOTS-c in 2026?
Worth knowing: a PCAC recommendation doesn't change what's legal today. Until the FDA formally adds a substance to the 503A Bulks List, through its own rulemaking process, compounding it under Section 503A remains outside the current framework.
For a running, substance-by-substance view of where individual peptides stand, see the FDA Peptide Status Tracker, and for the broader legal landscape peptides sit in more generally, see Are Peptides Legal in 2026?
Compounded Peptide vs. Research Chemical
It's worth drawing a clear line between two things that get talked about as if they're interchangeable, because they aren't.
A compounded peptide, if and when this becomes legally possible for a given substance, would require an individual patient's valid prescription from a licensed prescriber, prepared by a licensed compounding pharmacy, under FDA and state pharmacy board oversight. It would be a customized medical product tied to one patient's documented need.
A research-chemical peptide bought online and labeled "for research use only" is fundamentally different. It involves no prescription, no patient-specific customization by a pharmacist, and no pharmacy licensing oversight. It exists in a separate regulatory category entirely from a compounded drug. For a closer look at what that "research use only" label actually means and doesn't mean, see What Does "Research Use Only" Mean?
Frequently Asked Questions
Want to see how your own stack lines up? Run it through Rate My Stack, or build one from scratch with the Peptide Protocol Builder.